Rate My Professor Christopher Rowe

Rowe's research specializations encompass tools to assess and enhance quality of life for thyroid cancer patients, decision support aids for thyroid cancer treatment, management of acute glycaemic instability in pregnancy—particularly after glucocorticoid administration—and innovative parathyroid localisation methods. He has contributed book chapters including 'Thyroid Nodules and Thyroid Cancer Prior To, During, and Following Pregnancy' (2022) and 'Thyroid Cancer During Pregnancy and Lactation' (2020). Notable journal publications include 'Risk of Cancer Recurrence Exerts the Strongest Influence on Choice Between Active Surveillance and Thyroid Surgery as Initial Treatment for Low-Risk Thyroid Cancer' (2025), 'Determining the Accuracy of Continuous Glucose Monitoring During Periods of Acute Glycemic Variability in Pregnancy' (2025), and 'Spillover effects from a type 2 diabetes integrated model of care in 22,706 Australians' (2024). As the inaugural recipient of the HNELHD Clinical Research Fellowship, he has attracted over $1.3 million in funding across 13 grants from entities such as the Hunter Cancer Research Alliance, John Hunter Hospital Charitable Trust, University of Newcastle, and Avant Mutual Group. Rowe supervises MD and MPhil researchers, chairs research projects, and has earned awards like the International Association of the Diabetes and Pregnancy Study Group Best Oral Presentation Award (2022) and multiple outstanding abstract travel grants from ADIPS, Australian Diabetes Society, and Endocrine Society (USA).